$24.49 – $26.32: Is it good range for Arcutis Biotherapeutics Inc. (ARQT)


Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) changes shares on Tuesday trading session, with a change of -3.55% or -$0.92 shares. The trading starts at $25.60 and closed at $25.89 throughout the day. The trading session low price was $24.49 and day high was $26.32 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.1 million while its average volume is 83.11K. In other hand, the ARQT market cap reached to $985.57M. While, its current target price is $43.25.

On June 22, 2020, BRIEF-Arcutis Enrolls Last Patient In Phase 2 Proof Of Concept Clinical Trial Evaluating Arq-154. According to the news reported on Reuters, * ARCUTIS ENROLLS LAST PATIENT IN PHASE 2 PROOF OF CONCEPT CLINICAL TRIAL EVALUATING ARQ-154 (TOPICAL ROFLUMILAST FOAM) AS A POTENTIAL TREATMENT FOR SEBORRHEIC DERMATITIS

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -11.42% and down -22.65% for month. Its quarterly performance was -2.42% below, while its half year performance is down -2.61%. ARQT performance rise 14.54% for year-to-date. Current recommendation for Arcutis Biotherapeutics Inc. is 2.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. ARQT EPS (TTM) for 12-month is -2.12. EPS for this year is -118.10%, while for the next year its value is -3.84. Its EPS Q/Q reached -535.30%. It has an EPS of next five years will be up 22.90%.

Let’s take a look on the analyst recommendations on ARQT for the current month and previous month. For the current month, 3 of 4 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 3 analysts participate in stock recommendation. Out of 3, 0 rated it sell, 2 rated it as Buy and 1 as Hold Ratings.

Frazier Management LLC, FMR, LLC and Orbimed Advisors LLC. are the top three holders in Arcutis Biotherapeutics Inc. (ARQT) stock. On Mar 30, 2020, Frazier Management LLC has 10.54 million shares which valued 314.18 million. On Mar 30, 2020, FMR, LLC owned 5.71 million shares which valued at 170.26 million. On Mar 30, 2020, Orbimed Advisors LLC. has a total of 4.67 million shares which valued at 139.28 million. In the end, Orbimed Advisors LLC. have 12.25% shares outstanding of Arcutis Biotherapeutics Inc. (ARQT) on Mar 30, 2020. The insider ownership moved to 5.40% and institutional holding shifted to 86.00%.

The company posted an EPS (TTM) of -2.12. According to the most recent quarter report on (Jun 2020), 3 analysts estimated an average EPS of -0.84. Analyst Estimated EPS for ARQT published in the report was -$0.94 – -$0.72 during the same period.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for ARQT fall -11.52% for period of 200 days. SMA for 50 days was -16.50% which is showing red signal, while SMA-20 was -11.93%. The moving average value for Arcutis Biotherapeutics Inc. (ARQT) is 1.34M and 4.13% for 200 and 50 days respectively.